文献速递消化系统肿瘤胸部肿瘤支持与姑息治疗

奥氮平治疗局部晚期或转移性胃癌、肝胆胰癌和肺癌患者化疗相关厌食症的随机双盲安慰剂对照研究

Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
PubMed 文献 · J Clin Oncol · 2023-03-28

本研究纳入124例未治的局部晚期或转移性胃癌、肝胆胰癌或肺癌患者,随机双盲接受奥氮平2.5 mg每日一次或安慰剂12周,联合化疗。奥氮平组体重增加>5%的比例为60%对9%,食欲改善(VAS)为43%对13%,FAACT ACS评分≥37为22%对4%,差异均有统计学意义;奥氮平组生活质量、营养状态更好,化疗毒性更少,归因于奥氮平的副作用轻微。

要点

  • 奥氮平2.5 mg每日一次共12周,使体重增加>5%的患者比例达60%,显著高于安慰剂的9%。
  • 奥氮平组VAS食欲改善43%、FAACT ACS评分≥37者22%,均显著高于安慰剂组的13%和4%。
  • 奥氮平组生活质量、营养状态更好,化疗毒性更少;归因于奥氮平的副作用轻微。

核心结论

  • 低剂量每日奥氮平是一种简单、廉价、耐受良好的干预措施,可显著改善新诊断化疗患者的食欲和体重增加。

研究设计与样本

  • 随机双盲安慰剂对照试验,纳入124例(奥氮平组63例,安慰剂组61例)年龄≥18岁、未经治疗、局部晚期或转移性胃癌、肝胆胰癌或肺癌患者。
  • 奥氮平2.5 mg每日一次或安慰剂治疗12周,两组均接受标准营养评估和饮食建议,并联合化疗。
  • 可分析患者112例(奥氮平组58例,安慰剂组54例),中位年龄55岁(范围18-78岁);多数(99例,80%)为转移性癌症(胃癌68例[55%] > 肺癌43例[35%] > 肝胆胰癌13例[10%])。

主要发现

  • 奥氮平组体重增加>5%的患者比例高于安慰剂组(58例中35例[60%] 对 54例中5例[9%],P < .001)。
  • 奥氮平组VAS食欲改善比例高于安慰剂组(58例中25例[43%] 对 54例中7例[13%],P < .001)。
  • 奥氮平组FAACT ACS评分≥37的患者比例高于安慰剂组(58例中13例[22%] 对 54例中2例[4%],P = .004)。
  • 奥氮平组患者生活质量更好、营养状态更好、化疗毒性更少;归因于奥氮平的副作用轻微。

关键数值与推荐

  • 主要终点为体重增加>5%的患者比例和食欲改善(采用VAS和FAACT ACS评估)。
  • 次要终点为营养状态变化、生活质量和化疗毒性。
  • 奥氮平用法为2.5 mg每日一次,持续12周。

临床怎么用

  • 作者结论认为,低剂量每日奥氮平是一种简单、廉价、耐受良好的干预措施,可显著改善新诊断化疗患者的食欲和体重增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anorexia occurs in 30%-80% of patients with advanced malignancies, which may be worsened with chemotherapy. This trial assessed the efficacy of olanzapine in stimulating appetite and improving weight gain in patients receiving chemotherapy. METHODS: Adults (≥18 years) with untreated, locally advanced, or metastatic gastric, hepatopancreaticobiliary (HPB), and lung cancers were randomly assigned (double-blind) to receive olanzapine (2.5 mg once a day for 12 weeks) or placebo along with chemotherapy. Both groups received standard nutritional assessment and dietary advice. The primary outcomes were the proportion of patients with weight gain > 5% and the improvement in appetite (assessed by the visual analog scale [VAS] and the Functional Assessment of Chronic Illness Therapy system of Quality-of-Life questionnaires Anorexia Cachexia subscale [FAACT ACS]). Secondary end points were change in nutritional status, quality of life (QOL), and chemotherapy toxicity. RESULTS: We enrolled 124 patients (olanzapine, 63 and placebo, 61) with a median age of 55 years (18-78 years), of whom 112 (olanzapine, 58 and placebo, 54) were analyzable. The majority (n = 99, 80%) had metastatic cancer (gastric [n = 68, 55%] > lung [n = 43, 35%] > HPB [n = 13, 10%]). The olanzapine arm had a greater proportion of patients with a weight gain of > 5% (35 of 58 [60%] v 5 of 54 [9%], P < .001) and improvement in appetite by VAS (25 of 58 [43%] v 7 of 54 [13%], P < .001) and by FAACT ACS (scores ≥37:13 of 58 [22%] v 2 of 54 [4%], P = .004). Patients on olanzapine had better QOL, nutritional status, and lesser chemotoxicity. Side effects attributable to olanzapine were minimal. CONCLUSION: Low-dose, daily olanzapine is a simple, inexpensive, well-tolerated intervention that significantly improves appetite and weight gain in newly diagnosed patients on chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sandhya L, Devi Sreenivasan N, Goenka L, et al. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol. 2023. PMID: 36977285. doi:10.1200/JCO.22.01997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。